The INHABIT (synergIstic effect of aNtHocyAnin and proBIoTics in) Inflammatory Bowel Disease Trial: A double-blind randomised controlled trial assessing faecal calprotectin, gut microbiota profile and quality-of-life.

开始日期2023-11-01

申办/合作机构

University of Wollongong

CTRI/2023/08/056153 / Not yet recruiting临床4期

A randomized, double-blind, placebo-controlled study of digestive enzymes, carminatives & probiotics (Tummy soft drops) in the management of Infantile colic in infants. - NIL

开始日期2023-08-13

申办/合作机构-

100 项与 Live lactic acid bacteria probiotics(Vsl Pharmaceuticals, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Live lactic acid bacteria probiotics(Vsl Pharmaceuticals, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Live lactic acid bacteria probiotics(Vsl Pharmaceuticals, Inc.) 相关的专利（医药）

登录后查看更多信息

448

项与 Live lactic acid bacteria probiotics(Vsl Pharmaceuticals, Inc.) 相关的文献（医药）

2024-12-31·Gut microbes

Opioid-induced dysbiosis of maternal gut microbiota during gestation alters offspring gut microbiota and pain sensitivity

Article

作者: Singh, Salma ; Roy, Sabita ; Tao, Junyi ; Chupikova, Irina ; Abu, Yaa F ; Singh, Praveen ; Meng, Jingjing

There has been a rapid increase in neonates born with a history of prenatal opioid exposure. How prenatal opioid exposure affects pain sensitivity in offspring is of interest, as this may perpetuate the opioid epidemic. While few studies have reported hypersensitivity to thermal pain, potential mechanisms have not been described. This study posits that alterations in the gut microbiome may underly hypersensitivity to pain in prenatally methadone-exposed 3-week-old male offspring, which were generated using a mouse model of prenatal methadone exposure. Fecal samples collected from dams and their offspring were subjected to 16s rRNA sequencing. Thermal and mechanical pain were assessed using the tail flick and Von Frey assays. Transcriptomic changes in whole brain samples of opioid or saline-exposed offspring were investigated using RNA-sequencing, and midbrain sections from these animals were subjected to qPCR profiling of genes related to neuropathic and inflammatory pain pathways. Prenatal methadone exposure increased sensitivity to thermal and mechanical pain and elevated serum levels of IL-17a. Taxonomical analysis revealed that prenatal methadone exposure resulted in significant alterations in fecal gut microbiota composition, including depletion of Lactobacillus, Bifidobacterium, and Lachnospiracea sp and increased relative abundance of Akkermansia, Clostridium sensu stricto 1, and Lachnoclostridium. Supplementation of the probiotic VSL#3 in dams rescued hypersensitivity to thermal and mechanical pain in prenatally methadone-exposed offspring. Similarly, cross-fostering prenatally methadone-exposed offspring to control dams also attenuated hypersensitivity to thermal pain in opioid-exposed offspring. Modulation of the maternal and neonatal gut microbiome with probiotics resulted in transcriptional changes in genes related to neuropathic and immune-related signaling in whole brain and midbrain samples of prenatally methadone-exposed offspring. Together, our work provides compelling evidence of the gut-brain-axis in mediating pain sensitivity in prenatally opioid-exposed offspring.

2023-12-31·Gut microbes

Cholestasis: exploring the triangular relationship of gut microbiota-bile acid-cholestasis and the potential probiotic strategies

Review

作者: Chen, Wei ; Liu, Yaru ; Wang, Shunhe ; Narbad, Arjan ; Zhai, Qixiao ; Zhang, Hao ; Yu, Leilei ; Zhang, Qingsong ; Tian, Fengwei ; Zhao, Jianxin

Cholestasis is a condition characterized by the abnormal production or excretion of bile, and it can be induced by a variety of causes, the factors of which are extremely complex. Although great progress has been made in understanding cholestasis pathogenesis, the specific mechanisms remain unclear. Therefore, it is important to understand and distinguish cholestasis from different etiologies, which will also provide indispensable theoretical support for the development of corresponding therapeutic drugs. At present, the treatment of cholestasis mainly involves several bile acids (BAs) and their derivatives, most of which are in the clinical stage of development. Multiple lines of evidence indicate that ecological disorders of the gut microbiota are strongly related to the occurrence of cholestasis, in which BAs also play a pivotal role. Recent studies indicate that probiotics seem to have certain effects on cholestasis, but further confirmation from clinical trials is required. This paper reviews the etiology of and therapeutic strategies for cholestasis; summarizes the similarities and differences in inducement, symptoms, and mechanisms of related diseases; and provides information about the latest pharmacological therapies currently available and those under research for cholestasis. We also reviewed the highly intertwined relationship between gut microbiota-BA-cholestasis, revealing the potential role and possible mechanism of probiotics in the treatment of cholestasis.

2023-12-01·JBMR plus

Lactobacillus Reuteri 6475 Prevents Bone Loss in a Clinically Relevant Oral Model of Glucocorticoid‐Induced Osteoporosis in Male CD‐1 Mice

Article

作者: Gardinier, Joseph D ; Schepper, Jonathan D ; McCabe, Laura R ; Chargo, Nicholas J ; Kang, Ho Jun ; Rios‐Arce, Naoimy ; Parameswaran, Narayanan

ABSTRACT:

Glucocorticoids (GCs) are commonly used anti‐inflammatory medications with significant side effects, including glucocorticoid‐induced osteoporosis (GIO). We have previously demonstrated that chronic subcutaneous GC treatment in mice leads to gut barrier dysfunction and trabecular bone loss. We further showed that treating with probiotics or barrier enhancers improves gut barrier function and prevents GIO. The overall goal of this study was to test if probiotics could prevent GC‐induced gut barrier dysfunction and bone loss in a clinically relevant oral‐GC model of GIO. Eight‐week‐old male CD‐1 mice were treated with vehicle or corticosterone in the drinking water for 4 weeks and administered probiotics Lactobacillus reuteri ATCC 6475 (LR 6475) or VSL#3 thrice weekly via oral gavage. As expected, GC treatment led to significant gut barrier dysfunction (assessed by measuring serum endotoxin levels) and bone loss after 4 weeks. Serum endotoxin levels significantly and negatively correlated with bone volume. Importantly, LR 6475 treatment effectively prevented both GC‐induced increase in serum endotoxin and trabecular bone loss. VSL#3 had intermediate results, not differing from either control or GC‐treated animals. GC‐induced reductions in femur length, cortical thickness, and cortical area were not affected by probiotic treatment. Taken together, these results are the first to demonstrate that LR 6475 effectively prevents the detrimental effects of GC treatment on gut barrier, which correlates with enhanced trabecular bone health in an oral mouse model of GIO. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

项与 Live lactic acid bacteria probiotics(Vsl Pharmaceuticals, Inc.) 相关的新闻（医药）

2023-07-24

·PRNewswire

Digestive Health Supplements to grow by USD 7.86 billion from 2022 to 2027|Growing awareness about digestive health drives the market - Technavio

NEW YORK, July 24, 2023 /PRNewswire/ -- The digestive health supplements market is set to grow by USD 7.86 billion from 2022 to 2027, progressing at a CAGR of 7.12% during the forecast period. The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. Growing awareness about digestive health is the major factor notably driving market growth. Consumers are becoming more aware of the importance of digestive health and its impact on overall health and well-being. Many health problems can result from poor digestive health, including digestive disorders, autoimmune diseases, and even mental health issues. As people seek all-natural ways to support their health, the demand for digestive supplements is on the rise. The global digestive health supplement market is largely driven by the growing awareness regarding digestive health and the impact of digestive health on overall health. Probiotics, prebiotics, and digestive enzymes, amongst other organic ingredients that can improve gut health and treat digestive issues, are becoming popular among consumers as dietary supplements. Consumers are expected to prioritize their digestive health and opt for natural methods to enhance it. Henceforth, owing to the increase in awareness, the market in focus will grow during the forecast period. Here is an Exclusive report talking about Market scenarios with a historical period (2017-2021) and forecast period (2023-2027). Download Sample Report in minutes! Continue Reading Technavio has announced its latest market research report titled Global Digestive Health Supplements Market 2023-2027 The digestive health supplements market covers the following areas: Digestive Health Supplements Market Sizing Digestive Health Supplements Market Forecast Digestive Health Supplements Market Analysis. Digestive Health Supplements Market 2023-2027 - Market Dynamics Significant Digestive Health Supplements Market Trends The increasing popularity of probiotics and prebiotics is an emerging trend supporting market growth. A significant trend in the global digestive supplement market is the increasing significance of probiotics and prebiotics. Probiotics consist of live microorganisms that offer digestive and gut health benefits, while prebiotics are dietary fibers that contain beneficial bacteria. These ingredients are widely incorporated in digestive supplements due to their ability to promote a healthy gut microbiome and address common digestive issues like bloating, gas, and constipation. Moreover, research has linked a healthy gut microbiome to overall well-being, including immune function, mental health, and weight management. The demand for digestive health supplements that include probiotics and prebiotics is driven by consumers seeking to support their gut health. Market players are also investing in research and development to develop specialized and more effective compositions of probiotics and prebiotics for treating digestive problems. These factors contribute to the growing demand for digestive health supplements in the market. Major Digestive Health Supplements Market Challenge Increasing pricing pressures are the significant challenge hindering market growth. One of the major challenges in the global digestive health supplement market is the limited consumer awareness regarding the benefits of these supplements. Despite the growing popularity of these products, many consumers remain unaware of the advantages they offer. This lack of awareness can result in reduced demand as consumers may be hesitant to invest in premium products without understanding their potential benefits. Moreover, the lack of awareness can create uncertainty among consumers about the reliability and safety of digestive health supplements, further impacting their confidence in using such products. To address this challenge, market participants need to allocate resources to educational and awareness campaigns that aim to inform consumers about the advantages of these supplements. By enhancing consumer understanding, the market can overcome the obstacle of limited awareness and foster growth during the forecast period. What's New? - Special coverage on the Russia-Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession Global competitiveness and key competitor positions Market presence across multiple geographical footprints - Strong/Active/Niche/Trivial - Buy the report! Digestive Health Supplements Market 2023-2027: Market Segmentation This digestive health supplements market report extensively covers market segmentation by distribution channel (offline and online), type (prebiotics, probiotics, digestive enzymes, and others), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The market share growth by the offline segment will be significant during the forecast period. Offline distribution channel includes retail outlets, drug stores and pharmacies, and supermarkets. The offline distribution channel contributes to a more significant share of sales compared with online distribution channels. In developing countries such as India, China, and Brazil, consumers prefer to buy digestive health supplements from pharmacies or drug stores with prior consultation from healthcare practitioners or dieticians. The market share growth by the offline segment will be significant during the forecast period. Offline distribution channel includes retail outlets, drug stores and pharmacies, and supermarkets. The offline distribution channel contributes to a more significant share of sales compared with online distribution channels. In developing countries such as India, China, and Brazil, consumers prefer to buy digestive health supplements from pharmacies or drug stores with prior consultation from healthcare practitioners or dieticians. Companies Mentioned Amway Corp. Bayer AG Danone SA FRISKA LLC GNC Holdings LLC Hamari Chemicals Ltd. HealthForce SuperFoods Inc. Herbalife International of America Inc. Koninklijke DSM NV Lonza Group Ltd. Nestle SA Novozymes AS NOW Health Group Inc. Organic India PanTheryx Inc. Pfizer Inc. Twinlab Consolidated Corp. Unilever PLC Zenwise LLC Haleon Plc Vendors Offerings Amway Corp. - The company offers digestive health supplements such as Nutrilite digestive enzyme. Bayer AG - The company offers digestive health supplements such as Rennie. Danone SA - The company offers digestive health supplements through its subsidiary Nutricia. Gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform Related Reports: The Europe nutrition supplements market size is projected to increase by USD 20.93 billion and the market is estimated to grow at a CAGR of 5.74% between 2022 and 2027. This report extensively covers market segmentation by distribution channel (offline and online), and type (vitamins, botanicals, proteins and amino acids, minerals, and others). Increasing demand for plant-based supplements is a key trend driving the nutrition supplements market in Europe. The vegan supplements market share is expected to increase to USD 3.43 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.1%. This report extensively covers vegan supplements market segmentation by distribution channel (offline and online) and geography (Europe, North America, APAC, South America, and the Middle East and Africa). One of the key factors driving growth in the vegan supplements market is the expanding global vegan population base. Key Topics Covered: 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel Exhibit 06: Executive Summary – Chart on Market Segmentation by Type Exhibit 07: Executive Summary – Chart on Incremental Growth Exhibit 08: Executive Summary – Data Table on Incremental Growth Exhibit 09: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 10: Parent market Exhibit 11: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 12: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 13: Market segments 3.3 Market size 2022 3.4 Market outlook: Forecast for 2022-2027 Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion) Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion) Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) 4 Historic Market Size 4.1 Global digestive health supplements market 2017 - 2021 Exhibit 18: Historic Market Size – Data Table on Global digestive health supplements market 2017 - 2021 ($ billion) 4.2 Distribution Channel Segment Analysis 2017 - 2021 Exhibit 19: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ billion) 4.3 Type Segment Analysis 2017 - 2021 Exhibit 20: Historic Market Size – Type Segment 2017 - 2021 ($ billion) 4.4 Geography Segment Analysis 2017 - 2021 Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion) 4.5 Country Segment Analysis 2017 - 2021 Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion) 5 Five Forces Analysis 5.1 Five forces summary Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 5.2 Bargaining power of buyers Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027 5.3 Bargaining power of suppliers Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027 5.4 Threat of new entrants Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027 5.5 Threat of substitutes Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027 5.6 Threat of rivalry Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027 5.7 Market condition Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 6 Market Segmentation by Distribution Channel 6.1 Market segments Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%) Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%) 6.2 Comparison by Distribution Channel Exhibit 32: Chart on Comparison by Distribution Channel Exhibit 33: Data Table on Comparison by Distribution Channel 6.3 Offline - Market size and forecast 2022-2027 Exhibit 34: Chart on Offline - Market size and forecast 2022-2027 ($ billion) Exhibit 35: Data Table on Offline - Market size and forecast 2022-2027 ($ billion) Exhibit 36: Chart on Offline - Year-over-year growth 2022-2027 (%) Exhibit 37: Data Table on Offline - Year-over-year growth 2022-2027 (%) 6.4 Online - Market size and forecast 2022-2027 Exhibit 38: Chart on Online - Market size and forecast 2022-2027 ($ billion) Exhibit 39: Data Table on Online - Market size and forecast 2022-2027 ($ billion) Exhibit 40: Chart on Online - Year-over-year growth 2022-2027 (%) Exhibit 41: Data Table on Online - Year-over-year growth 2022-2027 (%) 6.5 Market opportunity by Distribution Channel Exhibit 42: Market opportunity by Distribution Channel ($ billion) Exhibit 43: Data Table on Market opportunity by Distribution Channel ($ billion) 7 Market Segmentation by Type 7.1 Market segments Exhibit 44: Chart on Type - Market share 2022-2027 (%) Exhibit 45: Data Table on Type - Market share 2022-2027 (%) 7.2 Comparison by Type Exhibit 46: Chart on Comparison by Type Exhibit 47: Data Table on Comparison by Type 7.3 Prebiotics - Market size and forecast 2022-2027 Exhibit 48: Chart on Prebiotics - Market size and forecast 2022-2027 ($ billion) Exhibit 49: Data Table on Prebiotics - Market size and forecast 2022-2027 ($ billion) Exhibit 50: Chart on Prebiotics - Year-over-year growth 2022-2027 (%) Exhibit 51: Data Table on Prebiotics - Year-over-year growth 2022-2027 (%) 7.4 Probiotics - Market size and forecast 2022-2027 Exhibit 52: Chart on Probiotics - Market size and forecast 2022-2027 ($ billion) Exhibit 53: Data Table on Probiotics - Market size and forecast 2022-2027 ($ billion) Exhibit 54: Chart on Probiotics - Year-over-year growth 2022-2027 (%) Exhibit 55: Data Table on Probiotics - Year-over-year growth 2022-2027 (%) 7.5 Digestive enzymes - Market size and forecast 2022-2027 Exhibit 56: Chart on Digestive enzymes - Market size and forecast 2022-2027 ($ billion) Exhibit 57: Data Table on Digestive enzymes - Market size and forecast 2022-2027 ($ billion) Exhibit 58: Chart on Digestive enzymes - Year-over-year growth 2022-2027 (%) Exhibit 59: Data Table on Digestive enzymes - Year-over-year growth 2022-2027 (%) 7.6 Others - Market size and forecast 2022-2027 Exhibit 60: Chart on Others - Market size and forecast 2022-2027 ($ billion) Exhibit 61: Data Table on Others - Market size and forecast 2022-2027 ($ billion) Exhibit 62: Chart on Others - Year-over-year growth 2022-2027 (%) Exhibit 63: Data Table on Others - Year-over-year growth 2022-2027 (%) 7.7 Market opportunity by Type Exhibit 64: Market opportunity by Type ($ billion) Exhibit 65: Data Table on Market opportunity by Type ($ billion) 8 Customer Landscape 8.1 Customer landscape overview Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 9 Geographic Landscape 9.1 Geographic segmentation Exhibit 67: Chart on Market share by geography 2022-2027 (%) Exhibit 68: Data Table on Market share by geography 2022-2027 (%) 9.2 Geographic comparison Exhibit 69: Chart on Geographic comparison Exhibit 70: Data Table on Geographic comparison 9.3 North America - Market size and forecast 2022-2027 Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ billion) Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ billion) Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%) 9.4 Europe - Market size and forecast 2022-2027 Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ billion) Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ billion) Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%) 9.5 Asia - Market size and forecast 2022-2027 Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ billion) Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ billion) Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%) 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion) Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion) Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) 9.7 US - Market size and forecast 2022-2027 Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ billion) Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ billion) Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%) Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%) 9.8 China - Market size and forecast 2022-2027 Exhibit 91: Chart on China - Market size and forecast 2022-2027 ($ billion) Exhibit 92: Data Table on China - Market size and forecast 2022-2027 ($ billion) Exhibit 93: Chart on China - Year-over-year growth 2022-2027 (%) Exhibit 94: Data Table on China - Year-over-year growth 2022-2027 (%) 9.9 UK - Market size and forecast 2022-2027 Exhibit 95: Chart on UK - Market size and forecast 2022-2027 ($ billion) Exhibit 96: Data Table on UK - Market size and forecast 2022-2027 ($ billion) Exhibit 97: Chart on UK - Year-over-year growth 2022-2027 (%) Exhibit 98: Data Table on UK - Year-over-year growth 2022-2027 (%) 9.10 Germany - Market size and forecast 2022-2027 Exhibit 99: Chart on Germany - Market size and forecast 2022-2027 ($ billion) Exhibit 100: Data Table on Germany - Market size and forecast 2022-2027 ($ billion) Exhibit 101: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibit 102: Data Table on Germany - Year-over-year growth 2022-2027 (%) 9.11 Japan - Market size and forecast 2022-2027 Exhibit 103: Chart on Japan - Market size and forecast 2022-2027 ($ billion) Exhibit 104: Data Table on Japan - Market size and forecast 2022-2027 ($ billion) Exhibit 105: Chart on Japan - Year-over-year growth 2022-2027 (%) Exhibit 106: Data Table on Japan - Year-over-year growth 2022-2027 (%) 9.12 Market opportunity by geography Exhibit 107: Market opportunity by geography ($ billion) Exhibit 108: Data Tables on Market opportunity by geography ($ billion) 10 Drivers, Challenges, and Trends 10.1 Market drivers 10.2 Market challenges 10.3 Impact of drivers and challenges Exhibit 109: Impact of drivers and challenges in 2022 and 2027 10.4 Market trends 11 Vendor Landscape 11.1 Overview 11.2 Vendor landscape Exhibit 110: Overview on Criticality of inputs and Factors of differentiation 11.3 Landscape disruption Exhibit 111: Overview on factors of disruption 11.4 Industry risks Exhibit 112: Impact of key risks on business 12 Vendor Analysis 12.1 Vendors covered Exhibit 113: Vendors covered 12.2 Market positioning of vendors Exhibit 114: Matrix on vendor position and classification 12.3 Amway Corp. Exhibit 115: Amway Corp. - Overview Exhibit 116: Amway Corp. - Product / Service Exhibit 117: Amway Corp. - Key offerings 12.4 Bayer AG Exhibit 118: Bayer AG - Overview Exhibit 119: Bayer AG - Business segments Exhibit 120: Bayer AG - Key news Exhibit 121: Bayer AG - Key offerings Exhibit 122: Bayer AG - Segment focus 12.5 Danone SA Exhibit 123: Danone SA - Overview Exhibit 124: Danone SA - Business segments Exhibit 125: Danone SA - Key news Exhibit 126: Danone SA - Key offerings Exhibit 127: Danone SA - Segment focus 12.6 Haleon Plc Exhibit 128: Haleon Plc - Overview Exhibit 129: Haleon Plc - Product / Service Exhibit 130: Haleon Plc - Key offerings 12.7 Hamari Chemicals Ltd. Exhibit 131: Hamari Chemicals Ltd. - Overview Exhibit 132: Hamari Chemicals Ltd. - Product / Service Exhibit 133: Hamari Chemicals Ltd. - Key offerings 12.8 HealthForce SuperFoods Inc. Exhibit 134: HealthForce SuperFoods Inc. - Overview Exhibit 135: HealthForce SuperFoods Inc. - Product / Service Exhibit 136: HealthForce SuperFoods Inc. - Key offerings 12.9 Herbalife International of America Inc. Exhibit 137: Herbalife International of America Inc. - Overview Exhibit 138: Herbalife International of America Inc. - Product / Service Exhibit 139: Herbalife International of America Inc. - Key offerings 12.10 Koninklijke DSM NV Exhibit 140: Koninklijke DSM NV - Overview Exhibit 141: Koninklijke DSM NV - Business segments Exhibit 142: Koninklijke DSM NV - Key news Exhibit 143: Koninklijke DSM NV - Key offerings Exhibit 144: Koninklijke DSM NV - Segment focus 12.11 Lonza Group Ltd. Exhibit 145: Lonza Group Ltd. - Overview Exhibit 146: Lonza Group Ltd. - Business segments Exhibit 147: Lonza Group Ltd. - Key news Exhibit 148: Lonza Group Ltd. - Key offerings Exhibit 149: Lonza Group Ltd. - Segment focus 12.12 Nestle SA Exhibit 150: Nestle SA - Overview Exhibit 151: Nestle SA - Business segments Exhibit 152: Nestle SA - Key news Exhibit 153: Nestle SA - Key offerings Exhibit 154: Nestle SA - Segment focus 12.13 Novozymes AS Exhibit 155: Novozymes AS - Overview Exhibit 156: Novozymes AS - Business segments Exhibit 157: Novozymes AS - Key news Exhibit 158: Novozymes AS - Key offerings Exhibit 159: Novozymes AS - Segment focus 12.14 NOW Health Group Inc. Exhibit 160: NOW Health Group Inc. - Overview Exhibit 161: NOW Health Group Inc. - Product / Service Exhibit 162: NOW Health Group Inc. - Key offerings 12.15 Pfizer Inc. Exhibit 163: Pfizer Inc. - Overview Exhibit 164: Pfizer Inc. - Product / Service Exhibit 165: Pfizer Inc. - Key news Exhibit 166: Pfizer Inc. - Key offerings 12.16 Unilever PLC Exhibit 167: Unilever PLC - Overview Exhibit 168: Unilever PLC - Business segments Exhibit 169: Unilever PLC - Key news Exhibit 170: Unilever PLC - Key offerings Exhibit 171: Unilever PLC - Segment focus 12.17 Zenwise LLC Exhibit 172: Zenwise LLC - Overview Exhibit 173: Zenwise LLC - Product / Service Exhibit 174: Zenwise LLC - Key offerings 13 Appendix 13.1 Scope of the report 13.2 Inclusions and exclusions checklist Exhibit 175: Inclusions checklist Exhibit 176: Exclusions checklist 13.3 Currency conversion rates for US$ Exhibit 177: Currency conversion rates for US$ 13.4 Research methodology Exhibit 178: Research methodology Exhibit 179: Validation techniques employed for market sizing Exhibit 180: Information sources 13.5 List of abbreviations Exhibit 181: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

2023-05-29

·PRNewswire

Microbial Products Global Market to 2027: Increasing Demand for Sustainable and Eco-friendly Solutions in Various Industries Drives Growth

DUBLIN, May 29, 2023 /PRNewswire/ -- The "Microbial Products: Technologies, Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering. The total global market for microbes and microbial products was worth $229.9 billion in 2021. The 2022 market is projected to exceed $242.0 billion, and the 2027 market is expected to approach $346.3 billion. This report addresses the global market for microbes and microbial products used in commercial applications from 2021 through 2027. This includes agricultural, healthcare, manufacturing, energy, and environmental applications. A microbial product refers to any substance produced by microorganisms, such as bacteria, fungi, and algae, that has commercial value. These products have become increasingly popular in various industries due to their eco-friendly nature and ability to provide sustainable solutions. One of the key drivers of the microbial product market is the increasing demand for sustainable and eco-friendly solutions in various industries, such as agriculture, healthcare, and food and beverage. Microbial products are also used in environmental remediation and biofuels, making them an attractive option for companies looking to reduce their carbon footprint. Some examples of microbial products in the market include probiotics, enzymes, biopesticides and biofertilizers. Probiotics, for instance, are used in the food and beverage industry to promote gut health and improve digestion. Biopesticides are used in agriculture to control pests and diseases while reducing the use of harmful chemicals. Biofertilizers, on the other hand, enhance plant growth and productivity by providing essential nutrients to the soil. Overall, the microbial product market is expected to continue to grow in the coming years as more industries adopt sustainable and eco-friendly practices. As the demand for these products increases, so will the research and development of new and innovative microbial products, making this a fascinating and dynamic field to watch. Report Includes 27 tables An overview of the global market and technologies for microbial products with special focus on their applications Estimation of the market size and analyses of global market trends, with data from 2019-2021, estimates for 2022 and projections of compound annual growth rates (CAGRs) through 2027 Highlights of the current and future market potential and quantification of microbial products market based on type, application, and region Detailed descriptions of probiotics, their types, and recent developments and information on microbial pesticides and biofertilizers and their potential uses Analysis of underlying technological, environmental, legal/regulatory, and political trends that may influence the size and nature of the market Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies Comprehensive company profiles of the leading players of the industry, including Seres Therapeutics, Enterome Biosciences, Ferring Pharmaceutics, Evelo Biosciences, Finch Therapeutics, Microbiome Therapeutics, and Pylum Biosciences Key Attributes: Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Market and Technology Background 3.1 General Description of Microbes 3.1.1 Definitions 3.1.2 Properties 3.1.3 Occurrence and Production 3.1.4 History 3.2 End Uses and Applications 3.2.1 Agriculture 3.2.2 Healthcare 3.2.3 Manufacturing 3.2.4 Energy 3.2.5 Environment 3.3 Market Size and Segmentation 3.3.1 Market Size and Growth 3.3.2 Market by End Use Chapter 4 Market for Agricultural Microbes and Microbial Products 4.1 Summary 4.2 Microbial Pesticides 4.2.1 Bacteria 4.2.2 Fungi 4.2.3 Protozoa 4.2.4 Nematodes 4.2.5 Markets 4.3 Microbial Fertilizers 4.3.1 Nitrogen Biofertilizers 4.3.2 Phosphorus Biofertilizers 4.3.3 Compost Treatment 4.3.4 Markets 4.4 Animal Feed Additives 4.4.1 Microbial Animal Feed Additive Types 4.4.2 Markets Chapter 5 Healthcare Market for Microbes and Microbial Products 5.1 Summary 5.2 Microbial Biopharmaceuticals 5.2.1 Technology 5.2.2 Markets 5.3 Therapeutics 5.3.1 Microbiome: Human and Non-Human 5.3.2 Probiotics Chapter 6 Manufacturing Market for Microbes and Microbial Products 6.1 Summary 6.2 Food Processing 6.2.1 Technologies 6.3 Enzymes 6.3.1 Technologies 6.3.2 Applications 6.4 Commodity and Specialty Chemicals 6.4.1 Technologies 6.5 Biopolymers 6.5.1 Technologies 6.5.2 Applications 6.5.3 Markets Chapter 7 Energy Market for Microbes and Microbial Products 7.1 Summary 7.2 Biofuels 7.2.1 Technology 7.2.2 Applications 7.3 Microbially Enhanced Oil Recovery 7.3.1 Technology 7.3.2 Applications 7.4 Microbial Fuel Cells 7.4.1 Technologies 7.4.2 Applications 7.5 Hydrogen Production 7.5.1 Technologies Chapter 8 Environmental Market for Microbes and Microbial Products 8.1 Summary 8.2 Environmental Monitoring 8.2.1 Technologies 8.2.2 Applications 8.3 Bioremediation 8.3.1 Technologies 8.4 Recycling 8.4.1 Technologies 8.5 Oil Spill and Residue Cleanup 8.5.1 Technologies 8.5.2 Applications 8.6 Wastewater and Sewage Treatment 8.6.1 Technologies 8.6.2 Applications Chapter 9 Regulation 9.1 U.S. 9.1.1 Department of Agriculture 9.1.2 Environmental Protection Agency 9.1.3 Food and Drug Administration 9.1.4 State-Level Regulations 9.2 European Union 9.2.1 Directive 98/81/Ec on the Contained Use of Genetically Modified Microorganisms 9.2.2 Directive 2001/18/Ec on the Deliberate Release into the Environment of Gmos 9.2.3 Regulation (Ec) No. 1107/2009 on the Placing of Plant Protection Products on the Market 9.2.4 Regulation (Ec) No 726/2004 on Procedures for the Authorization and Supervision of Medicinal Products for Human and Veterinary Use 9.2.5 Regulation 2015/2283 on Microorganisms Intentionally Added to Food 9.3 Japan 9.3.1 Food Sanitation Law 9.3.2 Feed Safety Law 9.4 Other Countries 9.4.1 Brazil 9.4.2 China 9.4.3 India 9.4.4 Russia 9.4.5 African Countries Chapter 10 Emerging/ Upcoming Technologies 10.1 Synthetic Biology 10.2 Crispr-Cas Technology 10.3 Metabolic Engineering 10.4 High-Throughput Screening 10.5 Nanoparticle Technology 10.6 Microfluidics 10.7 Omics Technologies Chapter 11 Patent Analysis Chapter 12 Competitive Landscape 12.1 Overview 12.1.1 Top 5 Companies 12.1.2 Global Company Ranking Chapter 13 Company Profiles For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

微生物疗法

2023-04-24

·Science Daily

A myth no more: Cranberry products can prevent urinary tract infections for women

Drinking cranberry juice has long been a mythical prevention strategy for women who develop a urinary tract infection -- and new medical evidence shows consuming cranberry products is an effective way to prevent a UTI before it gets started. A global study looking at the benefits of cranberry products has determined cranberry juice, and its supplements, reduce the risk of repeat symptomatic UTIs in women by more than a quarter, in children by more than half, and in people susceptible to UTI following medical interventions by about 53%. Drinking cranberry juice has long been a mythical prevention strategy for women who develop a urinary tract infection -- and new medical evidence shows consuming cranberry products is an effective way to prevent a UTI before it gets started. A global study looking at the benefits of cranberry products published in Cochrane Reviews has determined cranberry juice, and its supplements, reduce the risk of repeat symptomatic UTIs in women by more than a quarter, in children by more than half, and in people susceptible to UTI following medical interventions by about 53%. Cranberry juice and healthcare supplements that commonly include the fruit, such as capsules and tablets, have long been promoted as a readily available solution to ward off the infection but the most recent review in 2012, with evidence from 24 trials, showed no benefit from the products. The medical scientists behind this updated review from Flinders University and The Children's Hospital at Westmead aimed to update these findings, as an important step in determining the effectiveness of cranberry products by looking at 50 more recent trials that included almost 9000 participants. "This incredible result didn't really surprise us, as we're taught that when there's more and better evidence, the truth will ultimately come out. UTIs are horrible and very common; about a third of women will experience one, as will many elderly people and also people with bladder issues from spinal cord injury or other conditions," says the study lead author Dr. Gabrielle Williams. "Even back in 1973, my mum was told to try cranberry juice to prevent her horrible and frequent UTIs, and for her it's been a saviour. Despite me niggling in her ear about evidence, she's continued to take it daily, first as the nasty sour juice and in recent years, the easy to swallow capsules. As soon as she stops, wham the symptoms are back. As usual, it turns out that mum was right! Cranberry products can help some women prevent UTIs." Flinders University epidemiologist Dr. Jacqueline Stephens, a co-author of the study, says if the UTI persists untreated it can move to the kidneys and cause pain and more complications, including sepsis in very severe cases, so prevention is the most effective way to reduce risks. "Most UTIs are effectively, and pretty quickly, treated with antibiotics, sometimes as little as one dose can cure the problem. Unfortunately, in some people UTIs keep coming back. Without being sure if or how it works, some healthcare providers began suggesting it to their patients. It was a harmless, easy option at the time. Even centuries ago, Native Americans reportedly ate cranberries for bladder problems, leading somewhat more recently, to laboratory scientists exploring what it was in cranberries that helped and how it might work." "The studies we looked at included a range of methods to determine the benefits of cranberry products. The vast majority compared cranberry products with a placebo or no treatment for UTI and determined drinking cranberries as a juice or taking capsules reduced the number of UTIs in women with recurrent cases, in children and in people susceptible to UTi's following medical interventions such as bladder radiotherapy." "It's also important to consider that few people reported any side effects with the most common being tummy pain based on the results. We also did not find enough information to determine if cranberry products are more or less effective compared with antibiotics or probiotics in preventing further UTIs." The data also doesn't show any benefit for elderly people, pregnant women or in people with bladder emptying problems. Senior Author, Professor Jonathan Craig, Vice President and Executive Dean of the College of Medicine & Public Health at Flinders University, says the real benefits of cranberry products became clear when the researchers expanded the scope of the review to include the most recently available clinical data. "This is a review of the totality of the evidence and as new evidence emerges, new findings might occur. In this case, the new evidence shows a very positive finding that cranberry juice can prevent UTI in susceptible people," says Professor Craig. "We have shown the efficacy of cranberry products for the treatment of UTIs using all the evidence published on this topic since the mid-nineties. The earlier versions of this review didn't have enough evidence to determine efficacy and subsequent clinical trials showed varied results, but in this updated review the volume of data has shown this new finding." The study authors conclude that while cranberry products do help prevent UTIs in women with frequent recurrence, more studies are needed to further clarify who with UTI would benefit most from cranberry products.

100 项与 Live lactic acid bacteria probiotics(Vsl Pharmaceuticals, Inc.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Live lactic acid bacteria probiotics(Vsl Pharmaceuticals, Inc.)	A07FA01	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
溃疡性结肠炎	-	Vsl Pharmaceuticals, Inc.	-
肝性脑病	-	Vsl Pharmaceuticals, Inc.	-
肠易激综合征	-	Vsl Pharmaceuticals, Inc.	-
隐窝炎	-	Vsl Pharmaceuticals, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ChiCTR-TRC-13003332 (AACR2016)	临床4期	结直肠癌	60	Probiotic	繭顧壓齋壓鑰築艱鹽鹽(齋鏇夢鹹構廠網廠壓觸) = 鬱醖醖夢淵鑰選齋廠蓋鑰鏇鏇積醖壓齋構獵願 (製遞選製襯糧夢鹽網鹹 ) 更多	积极	2016-07-15
				Placebo	繭顧壓齋壓鑰築艱鹽鹽(齋鏇夢鹹構廠網廠壓觸) = 衊願衊蓋鹹網願襯淵衊鑰鏇鏇積醖壓齋構獵願 (製遞選製襯糧夢鹽網鹹 ) 更多
AAN2016	N/A	多发性硬化症 pro-inflammatory cytokines IL-17 \| IFN-γ \| anti-inflammatory cytokine IL-10	15	Probiotic VSL#3	網艱築獵膚選觸憲鏇製(膚遞獵艱醖簾顧範艱糧) = 憲範醖膚襯膚簾鑰構積網鹽艱醖鏇餘觸膚願選 (製鏇繭網廠網獵鹽膚鬱 ) 更多	积极	2016-04-05
				Placebo	網艱築獵膚選觸憲鏇製(膚遞獵艱醖簾顧範艱糧) = 繭憲遞遞鏇鹹糧觸窪襯網鹽艱醖鏇餘觸膚願選 (製鏇繭網廠網獵鹽膚鬱 ) 更多
NCT01110447 (Pubmed \| J Laparoendosc Adv Surg Tech A)	临床2/3期	纤维化	130	Probiotic VSL#3	壓顧遞襯衊繭夢鏇蓋鬱(廠廠餘蓋範鬱觸遞膚衊) = 獵範夢遞窪網選鹽齋醖範齋構觸遞鏇築窪鹽齋 (淵窪艱獵壓構範餘網蓋, 0.38 ~ 1.11) 更多	-	2014-12-01
				Placebo	壓顧遞襯衊繭夢鏇蓋鬱(廠廠餘蓋範鬱觸遞膚衊) = 夢窪鬱鏇壓廠獵觸範簾範齋構觸遞鏇築窪鹽齋 (淵窪艱獵壓構範餘網蓋 ) 更多